Before stem cell or regenerative medicine treatment in Japan, request the documents for the route being offered. For treatment under the Act on the Safety of Regenerative Medicine, ask for the filed provision plan and number, the committee’s written opinion, the cell-processing facility’s license, certification or notification, and the explanation and consent forms. If an approved product is being used, request its approval number and current package insert. If the offer is research, request the protocol, ethics approval and trial registration. These are six document groups, not six papers that every patient must obtain. Index
Ask for copies before committing to treatment or a non-refundable payment. A filed plan is not an efficacy approval. Also, treatment using only an approved product within its approved uses is excluded from the safety-law definition; it does not automatically require a separate provision plan. Ask the treating institution to identify the legal basis for your exact treatment. Plan

Which documents apply to your treatment?
Japan’s safety law regulates covered regenerative medicine provided as medical practice or research. The Pharmaceuticals and Medical Devices Act, or PMD Act, regulates regenerative medical products and their development. The Pharmaceuticals and Medical Devices Agency (PMDA) reviews products; the Ministry of Health, Labour and Welfare (MHLW) grants product approval. These are different from a clinic’s provision-plan filing. Index
For treatment covered by the safety law, check whether the plan is Class 1, 2 or 3. The class determines the review and filing procedures, not a success rate. PMD Act registration trials follow a different pathway and are excluded from the safety law’s definition of regenerative medicine. Research and ordinary clinical services are not interchangeable labels. Plan
An amendment effective on 31 May 2025 extended the safety framework to certain in vivo gene therapies and changed related procedures. Request the current documents rather than assuming an old version still covers the proposed intervention. Index
The six document groups
Use the applicable rows below. Requesting a document is a due-diligence step, not a claim that every attachment or confidential record must be released to patients.
| Document group | When to request it | What to match | What it does not establish |
|---|---|---|---|
| Filed provision plan and plan number | Treatment covered by the safety law | Institution, treatment, risk class, responsible doctor, cell source, dose and administration route | Product approval or clinical benefit |
| Certified committee’s written opinion | A provision plan requiring committee review | Committee name, plan version, opinion date and conditions | PMDA product approval or guaranteed safety |
| Cell-processing facility license, certification or notification | Processing of specified cells under the safety law | Facility name, address, identifier and work performed | Whether the treatment works for your disease |
| Explanation and consent forms | Every proposed treatment or research intervention | The intervention you will actually receive, risks, alternatives, costs and follow-up | That signing makes an intervention effective or suitable |
| Product approval details and current package insert | A claim that an approved product will be used | Product, approved indication, dose, route, warnings and conditions | Approval for every disease or every use |
| Research protocol, ethics approval and registration | An offer to join research | Study identifier, participating site, recruitment status, eligibility and protocol version | That registration proves benefit or permits commercial marketing |
The provision plan
Request the current filed plan, its number, filing date and relevant attachments. Ask which sections describe your treatment and whether there have been changes. Non-research safety-law plans are submitted through e-Regenerative Medicine; research plans under that law use jRCT. Substantive safety-related changes require prior submission after committee review, while minor changes follow a different notification procedure. Plan
Match your diagnosis, cell source and processing method, dose, administration route and number of administrations. Adipose-derived cells, bone-marrow-derived cells, cultured cells and same-day preparations should not be treated as interchangeable. Check the treating institution separately from any travel agent or payment intermediary; if different organizations appear, ask each one’s role.
A 2026 analysis of 41 non-research plans for spinal cord injury illustrates why these details matter. It used public records available in November 2025: 28 plans used adipose-derived cells and 13 used bone-marrow-derived cells, approximately 68% and 32%. Administration was intravenous in 29 plans, intrathecal in 11, and both in one. Only three plans, about 7%, explicitly limited treatment to the chronic phase. These were plan descriptions, not observed patient outcomes. PMC13226842
The available information also had gaps. Culture duration was extractable from 28 plans, with four weeks listed in 20; cell dose was extractable from 21 plans, with 1.0 × 10^8 cells listed in 16. Prices were available for 40 plans, averaging US$14,100 after conversion at ¥150 per US dollar. That is a historical dataset average, not a national price benchmark or a treatment recommendation. The study did not establish benefit or safety for patients. PMC13226842
The committee opinion
Request the committee’s name, the written opinion for your plan, the review date and any conditions. Class 1 and Class 2 plans require a specially certified committee; Class 3 plans require a committee authorized to review that class. Verify the committee against MHLW’s published lists. 0000150542_00003
If the plan changed after the opinion, ask for the relevant change-review documents. A specially certified committee must meet composition requirements, including at least eight members and independence safeguards. Certification and a favorable opinion do not guarantee benefit or freedom from harm. Ask how conflicts involving the clinic or processing company were managed. 0000150542_00003
The cell-processing record
For specified cell processing under the safety law, request the facility’s license, certification or notification. A cell-processing center inside a Japanese medical institution uses a notification; a domestic facility outside a medical institution requires a license, and an overseas facility requires certification. The latter two routes include PMDA investigation. A notification is not a license. Manufacturiungfacility
Match the facility name, address and identifier to the work described in your plan. Ask which steps are outsourced. This facility regime concerns specified processed cells; it should not be confused with the manufacturing controls for an approved commercial product. Manufacturiungfacility
Request a summary of the release specifications and, when your batch exists, its test results. Ask which tests apply, their acceptance criteria, the actual results and whether any results will still be pending at administration. Examples to discuss include sterility, mycoplasma, endotoxin, viability, cell count, identity and potency. This is not a universal mandatory test panel: the specifications depend on the preparation. A facility permission alone is not a batch test result.
The consent documents
Request the exact explanation and consent forms you will receive, with a written translation you can understand. MHLW publishes explanation and consent documents associated with filed plans, but a public template is not your individual signed consent record. Compare the version and treatment details before signing. 0000186471
Look for the reason treatment is proposed, the cell source, processing, dose, route and number of sessions. Ask what benefit is supported, what remains unknown, and whether the intervention is approved, investigational or a private clinical service. Ask for risks associated with both the cells and the procedure, including collection or injection where applicable. The form should explain alternatives, expected follow-up, emergency contacts, costs and what happens if treatment is stopped or a complication occurs.
A brochure is not a substitute. Japan’s medical advertising rules restrict misleading claims and regulate the presentation of treatment details, costs, risks, testimonials and before-and-after photographs. If advertising and the consent document disagree, request a written explanation from the treating institution. Index
Signing records consent; it does not by itself establish that every risk was understood or that the treatment is approved, effective or appropriate for you.
The product approval and label
If an approved product is proposed, request its exact name, approval number and current package insert. Ask for the approval certificate or an official record if available. Check the approved indication, patient group, dose, route, warnings and any conditional or time-limited status against PMDA’s product information. An English review report can be historical and may lag the Japanese documents. 0003
For example, the 2015 Temcell review report describes donor bone-marrow-derived mesenchymal stem cells for acute graft-versus-host disease after hematopoietic stem cell transplantation. It lists 72 million cells per 10.8 mL bag and a usual dose of 2 million cells/kg by slow intravenous infusion, twice weekly for four weeks. Its original approval was not conditional and time-limited; it had a 10-year re-examination period and an all-patient use-results survey condition. These historical details illustrate what to check, not a dosing recommendation or confirmation of today’s label. 000215658.pdf
HeartSheet provides a different example. Its 2015 approval for severe heart failure due to ischemic heart disease was conditional and time-limited, initially for five years, with post-marketing evaluation of treated patients. It is an autologous skeletal-muscle-cell sheet, not the same product as Temcell. 000215222.pdf PMDA’s review-report page states that full approval was rejected as of 24 July 2024. An old approval certificate therefore cannot replace a current-status check. 0004
If your diagnosis, dose or route differs from the approved use, ask whether the proposal is off-label, what evidence supports it and which legal requirements apply. Approval of a product is not approval of every protocol using it.
The research documents
Request the registration identifier, protocol or patient-facing protocol summary, ethics or institutional review board approval, participating-site details and research consent form. Ask about insurance or compensation arrangements, conflicts of interest and the legal pathway. For Japanese safety-law research, match the plan in jRCT; do not assume that every study described as a clinical trial follows the same rules. Jrct.mhlw.go.jp
Check the condition and disease stage, cell source, dose, route, trial phase where applicable, sample size, comparison group, primary endpoint, follow-up and adverse-event plan. Confirm that your institution is a participating site and that the study is recruiting eligible patients. Ask who pays for treatment, testing and follow-up, and what happens if you withdraw.
Registration alone does not establish efficacy, safety or marketing authorization. FDA specifically warns that inclusion in ClinicalTrials.gov, or a firm’s registration with FDA, does not mean a product is legally marketed. Read the study record and any results rather than treating the identifier as an approval number. Important patient and consumer information about regenerative medicine therapies
Supporting records and timing
Ask for the regulatory and consent documents before committing. Batch-specific records may only become available after collection and processing, so request the specifications first and agree how the final results will be provided. Ask for anonymized summaries where records contain other people’s private information.
- Traceability and donor screening. For donor cells, ask for a screening summary and how the donation is traced to your batch. For your own cells, ask how identity is maintained through collection, processing and administration. Do not request another person’s identifiable medical records.
- Processing summary. Ask for culture duration, passage number where applicable, relevant materials and final formulation, and how these match the proposed treatment.
- Follow-up and emergency plan. Ask who will examine you, when, which tests repeat and who handles complications after you return home. Include these arrangements in your treatment process in Japan, rather than leaving them to a coordinator’s verbal assurance.
- Safety-reporting procedure. Under the safety-law procedure, suspected treatment-related deaths or life-threatening cases must be reported within 7 days after the provider learns of the event; specified other serious events, including hospitalization or disability, within 15 days, to the committee and relevant regulator. These are provider reporting deadlines, not advice to wait before seeking care. Plan
- Annual safety summary. Ask for treatment-specific patient numbers and adverse-event information, with the reporting period and denominator. Under the safety law, the annual report is due within 90 days after each one-year reporting period. A summary is not a controlled efficacy study. Plan
- Records and access. Ask how to obtain copies later. MHLW’s safety-law guidance specifies 10-year retention for the general category and 30 years for specified biological-product or related-material categories. Have the provider identify which applies; these are not blanket retention periods for every medical record. Plan
- Itemized quote and contract. For stem cell treatment costs in Japan, request separate amounts for consultation, tests, collection, processing, administration, medicines and follow-up, plus exclusions, repeat-treatment charges and complication care. Read cancellation and refund terms before paying.
How to verify the documents
Compare identifiers, dates and treatment details across the documents, not just certificate logos. Browser translation may help you navigate Japanese records, but it is not a reliable substitute for a professional explanation of clinical or legal wording.
| Document or identifier | Where to check | Question to resolve |
|---|---|---|
| Provision-plan number and institution | MHLW’s published provider and plan information. 0000186471 | Does the record identify the institution, treatment, class, committee and associated consent documents? |
| Committee name | MHLW’s certified committee lists. 0000150542_00003 | Is it certified for the relevant class, and does the opinion concern this plan? |
| Processing facility | License, certification or notification and the responsible authority. Manufacturiungfacility | Does the facility identifier match the processing described? |
| Product approval number | PMDA’s product information and current label. 0003 | Does the approved indication and route match the offer, and what conditions apply? |
| Study identifier | jRCT or the registry named by the research team. Jrct.mhlw.go.jp | Do the site, eligibility, intervention and recruitment status match? |
MHLW’s public information also includes administrative orders. Checking those is part of assessing a stem cell hospital in Japan, not proof that an unlisted provider is safe. A public listing may lag changes; request the filed version and written clarification if information differs. 0000186471
A worked document check
Suppose a treatment quote describes an intravenous infusion into a vein, but the consent form describes an intrathecal injection into the fluid surrounding the spinal cord. Do not treat the two routes as interchangeable. Ask the doctor to identify the intended route, show where it appears in the applicable plan or product label, and provide matching consent documents before proceeding. This is an illustrative checking scenario, not a patient case or evidence that either route is suitable.
Keep a simple record: document title, identifier, version date, relevant page, mismatch and written reply. Save complete PDFs rather than cropped certificate screenshots. If a full protocol or attachment cannot be shared, ask what is confidential and request a patient-facing summary; a refusal alone does not prove unlawful treatment.
Missing or mismatched documents
For a treatment that requires a provision plan, a missing number or an unexplained disease, cell-source, dose or route mismatch is a reason to pause a non-refundable payment. Request the applicable filed change or a written explanation. For an approved product used within its approved conditions, the absence of a separate safety-law plan is not, by itself, a violation. Plan
If you suspect a safety-law violation, MHLW’s reporting desk covers matters such as missing plans, missing committee review, treatment inconsistent with a plan and safety or quality concerns. Its role is distinct from general regenerative medicine registration and compliance information; it does not provide individual medical assessments or resolve compensation disputes. Madoguchi Suspected advertising violations can be sent to the medical institution network patrol. Iryoukoukoku patrol.mhlw.go.jp For contract disputes in Japan, the Consumer Hotline is 188; availability and language support should be checked locally. Madoguchi
What paperwork cannot establish
A plan, committee opinion or facility record cannot establish that the proposed treatment will help you. Ask for human studies matching your diagnosis and stage, cell preparation, dose and route, with meaningful endpoints, an appropriate comparison where possible, follow-up and adverse-event reporting. PubMed indexing alone is not a quality assessment.
Have a clinician independent of the provider review the evidence and your alternatives. A facility identifier does not establish the doctor’s experience, emergency capacity or the balance of benefits and harms for your case. Do not delay standard treatment or specialist follow-up while collecting documents.
Equivalent documents outside Japan
In the United States, ask which FDA pathway applies to the exact product and use. For a product claimed to be approved, request the approval details and current label. For an investigational product, request the study identifier, informed consent, institutional review board details and confirmation of the applicable FDA oversight; an IND number is not a marketing approval. FDA reports serious harms, including blindness, tumors and infections, from unapproved regenerative medicine products. Its consumer warning is not a current comprehensive list of approved cell therapies. Important patient and consumer information about regenerative medicine therapies
In the European Union, request the EU marketing authorization and approved indication, or the written basis for another lawful pathway and confirmation from the relevant national authority. EMA evaluates centrally authorized advanced therapy medicines; the European Commission makes the authorization decision. EMA advises checking suspicious offers with the national competent authority, particularly when a provider markets a therapy as experimental without an authorized trial or cannot confirm the basis for lawful use. Japanese paperwork does not substitute for authorization elsewhere. Advanced therapy medicinal products overview
A request you can copy
Before I commit to treatment or a non-refundable payment, please confirm the legal pathway for the exact intervention proposed for me and send the applicable documents:
- If the treatment falls under Japan’s regenerative medicine safety law, the current filed provision plan and number, relevant attachments, committee opinion and cell-processing facility license, certification or notification.
- The explanation and consent documents I will receive, with a written translation I can understand.
- If an approved product is proposed, its name, approval number, current package insert, approved indication and any conditional or time-limited status.
- If this is research, the registration identifier, protocol or patient-facing summary, ethics approval, participating-site confirmation and research consent form. Please identify the jRCT or ClinicalTrials.gov record where applicable. Jrct.mhlw.go.jp Clinicaltrials.gov
- The proposed release specifications and the timing for providing my batch’s results, plus donor-screening and traceability summaries where applicable.
- The follow-up and emergency plan, compensation or insurance arrangements, itemized quote and cancellation and refund terms.
Please confirm my diagnosis, cell source and processing, dose, administration route and number of administrations in writing. If a requested document does not apply or cannot be shared, please explain why and provide an appropriate alternative.
Ask the named treating doctor to explain unresolved clinical questions. A coordinator can help obtain documents but cannot replace the doctor’s explanation or an independent medical opinion.
Need to ask which documents are available?
Contact the clinic’s patient support team about the proposed treatment, document availability and language assistance. This is an inquiry, not regulatory certification or an independent medical review.
Before you decide
Request the document groups that match the legal pathway, check the identifiers and treatment details, and resolve discrepancies in writing. The safety law’s definitions, risk classes and provision-plan duties are set out in Articles 2 and 4; product approval is a separate question. En Then ask what clinical evidence supports this exact intervention for your condition. A complete file is a starting point for that discussion, not a guarantee of benefit.
This guide focuses on Japan, with brief US and EU comparisons. It draws on official sources and a published analysis of plan documents; it is not a report of the author’s clinical practice or patient experience. Source checks were made on 23 and 27 October 2026. Rules and product information can change, and translations may lag the controlling Japanese documents. Confirm the applicable requirements with the provider and regulator. This is general information, not personal medical or legal advice. Seek urgent medical care for concerning symptoms rather than waiting for documents or a regulatory reply.




